Kura Oncology’s positive combo data could accelerate a new treatment option for advanced clear cell renal cell carcinoma
Executive summary: Kura Oncology reported that the combination of darlifarnib and cabozantinib achieved response rates up to 50% and a median progression‑free survival of 13 months in previously treated, cabozantinib‑naïve patients with advanced clear cell renal cell carcinoma, based on data presented at KCRS 2026. The results suggest a potentially effective new regimen for a hard‑to‑treat cancer indication, which could influence future treatment guidelines and affect the market positioning of both drugs.
Who is involved: Kura Oncology, clinical investigators participating in the FIT‑001 study, patients with advanced ccRCC, and the organizers of the KCRS 2026 conference.
Likely next: Further clinical development, including potential Phase 2 trials, and regulatory discussions with the FDA or EMA regarding a possible new drug application for the combination.
Kura Oncology reported that combining darlifarnib with cabozantinib produced objective response rates as high as 50% and a median progression‑free survival of 13 months in previously treated, cabozantinib‑naïve patients with advanced clear cell renal cell carcinoma. The data were presented at the KCRS 2026 conference and build on earlier long‑term follow‑up information shared by the company on July 14, 2026. While the findings are encouraging, they remain early‑stage and will need confirmation in larger trials before any regulatory or commercial impact can be realized.
Timeline
- — Kura Oncology Reports Durable Clinical Activity of Darlifarnib Plus Cabozantinib in Cabozantinib‑Naïve Clear Cell Renal Cell Carcinoma Patients at KCRS 2026 (GlobeNewswire)
- — Kura Oncology to Present First Long-Term Follow-Up Data Further Supporting Darlifarnib’s Potential to Enhance VEGFR-Targeted Therapy in Renal Cell Carcinoma at KCRS 2026 (GlobeNewswire)
Analysis — what this means
Sectors affected
- clear cell renal cell carcinoma therapeutics
- VEGFR‑targeted therapy combinations
Historical parallels
- Kura Oncology’s July 14 2026 announcement of upcoming long‑term follow‑up data for darlifarnib plus cabozantinib at KCRS 2026
Key entities
Sources
- Kura Oncology Reports Durable Clinical Activity of Darlifarnib Plus Cabozantinib in Cabozantinib‑Naïve Clear Cell Renal Cell Carcinoma Patients at KCRS 2026 — GlobeNewswire
- Kura Oncology to Present First Long-Term Follow-Up Data Further Supporting Darlifarnib’s Potential to Enhance VEGFR-Targeted Therapy in Renal Cell Carcinoma at KCRS 2026 — GlobeNewswire